Immunomodulatory molecules in colorectal cancer liver metastasis

Cancer Lett. 2024 Aug 28:598:217113. doi: 10.1016/j.canlet.2024.217113. Epub 2024 Jul 14.

Abstract

Colorectal cancer (CRC) ranks as the third most common cancer and the second leading cause of cancer-related deaths. According to clinical diagnosis and treatment, liver metastasis occurs in approximately 50 % of CRC patients, indicating a poor prognosis. The unique immune tolerance of the liver fosters an immunosuppressive tumor microenvironment (TME). In the context of tumors, numerous membrane and secreted proteins have been linked to tumor immune evasion as immunomodulatory molecules, but much remains unknown about how these proteins contribute to immune evasion in colorectal cancer liver metastasis (CRLM). This article reviews recently discovered membrane and secreted proteins with roles as both immunostimulatory and immunosuppressive molecules within the TME that influence immune evasion in CRC primary and metastatic lesions, particularly their mechanisms in promoting CRLM. This article also addresses screening strategies for identifying proteins involved in immune evasion in CRLM and provides insights into potential protein targets for treating CRLM.

Keywords: Colorectal cancer liver metastasis; Immunomodulatory molecule; Membrane protein; Secreted protein; Tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Colorectal Neoplasms* / immunology
  • Colorectal Neoplasms* / pathology
  • Humans
  • Liver Neoplasms* / immunology
  • Liver Neoplasms* / secondary
  • Tumor Escape
  • Tumor Microenvironment* / immunology